热门资讯> 正文
木薯科学公司将支付3125万美元和解证券集体诉讼
2025-12-23 21:38
- Cassava Sciences (SAVA) announced on Tuesday that it agreed to pay $31.25M to settle a class action lawsuit pending in a Texas District Court over the company’s alleged violations of the federal securities laws.
- The case filed in the U.S. District Court for the Western District of Texas, Austin Division, in 2021 relied on allegations contained in Citizen Petitions submitted to the FDA regarding Cassava’s (SAVA) lead asset, simufilam.
- In November 2024, the company suffered a late-stage trial setback for the once high-flying oral therapy targeted at Alzheimer's disease.
- “The settlement is not an admission of fault or wrongdoing by the Company,” Cassava (SAVA) said, adding that it has recorded a $31.25M provision in Q2 2025 to recognize a potential loss contingency related to the case.
More on Cassava Sciences
- Cassava Sciences: Fundamentals Update After Big Move On Insider Purchases
- Cassava Sciences drops on delay for epilepsy study
- Cassava Sciences hit with FDA request for more data on simufilam trial
- Seeking Alpha’s Quant Rating on Cassava Sciences
- Historical earnings data for Cassava Sciences
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
